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A 47-year-old male presented to the emergency department with 12 hours of nausea, vomiting, 
abdominal pain, and a widespread skin eruption with mottled, irregular, purpuric lesions with 
subsequent rapid decompensation. Laboratory analysis revealed thrombocytopenia, bandemia, 
elevated metamyelocytes, abnormal coagulation panel, decreased fibrinogen, elevated fibrin 
split products, renal dysfunction, bacterial rods, dohle bodies, and toxic granulation. Acute 
promyelocytic leukemia (APML) was confirmed via bone marrow biopsy, flow cytometry, and 
fluorescence in situ hybridization analysis. Disseminated intravascular coagulation (DIC) may be 
the initial presentation of APML. When treated promptly, APML can achieve high remission rates; 
however, conditions such as DIC continue to increase mortality requiring early recognition to 
improve survival rates. [Clin Pract Cases Emerg Med. 2019;3(4):446–448.]  
CASE PRESENTATION
A 47-year-old male with no past medical history 
presented with nausea, vomiting, diffuse abdominal pain, 
and a widespread rash that began 12 hours prior to arrival. 
Physical examination revealed an ill-appearing male with 
diffuse abdominal tenderness as well as diffuse purpuric, 
mottled skin (Image). Vital signs revealed a blood pressure 
of 93/74 millimeters of mercury, heart rate of 120 beats per 
minute, respiratory rate of 30 respirations per minute, and 
a rectal temperature of 103.7 degrees Fahrenheit with pulse 
oxygenation saturation of 94%. His course necessitated fluid 
boluses, vasopressors, broad-spectrum antibiotics, steroids, 
and intubation. 
His laboratory findings revealed bandemia, 
thrombocytopenia, acute kidney injury, elevated coagulation 
markers, decreased fibrinogen, elevated fibrin split products, 
elevated lactate dehydrogenase, and a lactic acidosis as 
shown in the Table, along with an unremarkable computed 
tomography of his abdomen and pelvis without contrast. 
The presumptive diagnosis was the development of acute 
promyelocytic leukemia (APML) with disseminated 
Inspira Medical Center, Department of Emergency Medicine, Vineland, New Jersey 
Image. Purpuric mottled skin eruption resulting from disseminated 
intravascular coagulation (arrow).
intravascular coagulation (DIC), an uncommon skin 
presentation called purpura fulminans (PF), and septic shock.
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What do we already know about this 
clinical entity? 
Acute promyelocytic leukemia (APML) 
is associated with a high incidence 
of fibrinolytic-type disseminated 
intravascular coagulation (DIC).Treatment 
is supportive.
What is the major impact of the image(s)?
The image reinforces what purpura fulminans 
looks like and highlights the occurrence of 
DIC in APML and the importance of early 
recognition and treatment.
How might this improve emergency 
medicine practice?  
Keeping a broad differential with 
knowledge of this emergent condition will 
yield earlier coordination of care and 
treatment of APML, which carries a high 
misdiagnosis and mortality rate.
Laboratory findings Values Reference ranges
White blood cell 9.9x103 x 1000/mm3 4-11 x 1000/mm3
Hemoglobin 16.1 g/dL 12-18 g/dL
Platelets 27 x103 x 1000/mm3 150-450 x 1000/mm3
Manual differential 26% bands, 6% metamyelocytes, as well as many 
bacteria rods, Dohle bodies, and evidence of 
toxic granulation.
Segmented neutrophils: 50%–70%. Band forms: 
0–5%. Lymphocytes: 30%–45%. Monocytes: 
0–6%. Basophils: 0–1%. Eosinophils: 0–3%
Coagulation panel Prothrombin time: 24.9 seconds, partial 
thromboplastin time: 151 seconds,  INR: 2.1
Prothrombin time: 11-13 seconds, partial 
thromboplastin time: 25-35 seconds, INR: 0.8-1.2
Fibrinogen <80 mg/dL 200-400 mg/dL
Fibrin split products >40 ug/ml <10 ug/ml
Creatinine 3.2 mg/dL 0.7-1.3 mg/dL
Lactate dehydrogenase 868 u/L 80-225 u/L
Lactic acid 11.5 mmol/L 0.7-2.1 mmol/L
DISCUSSION
The patient was transferred to a tertiary care center 
and underwent bone marrow biopsy, flow cytometry, and 
fluorescence in situ hybridization analysis confirming 
APML. APML constitutes 10% of all adult acute 
myelogenous leukemia and has a high incidence of life-
threatening hemorrhage secondary to fibrinolytic-type 
DIC, which has been attributed to both the development 
of APML as well as sepsis secondary to APML.1,2 There is 
a high misdiagnosis and delayed treatment rate secondary 
to the varied and complex presentation. APML results 
from chromosomal abnormalities that involve a balanced 
translocation between chromosomes 15 and 17 with an 
incidence of 600-800 cases annually in the United States.3 
The average age at time of diagnosis is between 20 and 50 
years of age.
APML should be considered in those with presentations 
of bleeding, DIC, or infections with laboratory 
abnormalities of thrombocytopenia, anemia, and subnormal 
to elevated white blood cell count. In cases of DIC, scoring 
algorithms use platelet count, level of fibrin markers such 
as d-dimer and fibrin split products, coagulation studies, 
and fibrinogen levels to arrive at a diagnosis. Additionally, 
with DIC, PF may also occur. PF is a poorly understood 
entity;  it occurs secondary to endovascular thrombotic 
events and endothelial damage, which contribute to 
the characteristic purpuric appearance.4 The mainstay 
of treatment is aggressive supportive care as well as 
identifying and treating the underlying coagulopathy and 
infections, in addition to induction therapy with all-trans-
retinoic-acid and chemotherapeutic agents in consultation 
with a hematologist.5
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
Table. Abnormal laboratory findings in patient diagnosed with acute promyelocytic leukemia.
mm3, cubic millimeters; g/dL, grams per deciliter; INR, international normalized ratio; mg/dL, milligrams per deciliter; ug/ml, micrograms per 
milliliter; mmol, millimoles; L, liter; u, unit.
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